{
  "guideline": {
    "id": "PA166182753",
    "name": "Annotation of FDA Label for meloxicam and CYP2C9",
    "source": "FDA",
    "version": 14,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182753",
    "relatedChemicals": [
      {
        "id": "PA450353",
        "name": "meloxicam",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312029",
      "name": "Recommendation Annotation PA166312029",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216228,
        "html": "<p>&quot;In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin or phenytoin), consider dose reduction, as these patients may have abnormally high plasma levels of meloxicam due to reduced metabolic clearance. Monitor these patients for adverse effects.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312030",
      "name": "Recommendation Annotation PA166312030",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216229,
        "html": "<p>&quot;In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin or phenytoin), consider dose reduction, as these patients may have abnormally high plasma levels of meloxicam due to reduced metabolic clearance. Monitor these patients for adverse effects.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Mobic (meloxicam), NDA020938, REMEDYREPACK INC.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020938"
    },
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product QMIIZ ODT (meloxicam), NDA211210, TerSera Therapeutics LLC",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211210"
    },
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Vivlodex (meloxicam), NDA207233, Egalet US Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207233"
    }
  ],
  "version": "2024-02-29-20-19"
}